Advertisment
Alnylam Pharmaceuticals to present new data on RNAi therapies for transthyretin amyloidosis and hypertension at 2024 AHA scientific sessions
Alnylam Pharmaceuticals, the leading RNAi therapeutics company, today announced that the Company will present data from its transthyretin amyloidosis (ATTR) and hypertension programs at the upcoming American Heart Association (AHA) Scientific Sessions 2024, November 16–18, 2024.
Data presentations for the Company’s flagship TTR franchise include new findings from an analysis of the HELIOS-B Phase 3 study of vutrisiran, an RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), as well as interim results from a Phase 1 study evaluating ALN-TTRsc04, a next generation RNAi therapeutic in development for the treatment of ATTR amyloidosis.
Full results from the HELIOS-B study, the largest and most contemporary ATTR-CM study to date, were published in The New England Journal of Medicine earlier this year. The study achieved all 10 pre-specified primary and secondary endpoints. In addition, the Company will present a new analysis of the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension.
ATTR Abstracts
A Phase 1, Single Ascending Dose Study to Evaluate ALN-TTRsc04, a Next-Generation RNA Interference Therapeutic, in Healthy Participants for Potential Treatment of Transthyretin Amyloidosis
Poster 4135443: Session: Cutting Edge Clinical Cardiomyopathies Research (Abstract Oral Session)
Sunday, November 17, 2024, 8:30 a.m. (CST), 9:30 a.m. (EST)
Presenting Author: Ali Murad
Impact of vutrisiran on outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial
Poster 4171680: Session: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations (Featured Science)
Monday, November 18, 2024, 10:21 a.m. (CST), 11:21 a.m. (EST)
Presenting Author: Marianna Fontana
Hypertension Abstracts
Impact of Long-Term Blood Pressure Variability on Adverse Cardiovascular Outcomes in High- and Low-Risk Populations
Poster MDP1200: Session: The Threats of Hypertension to Life and Healthy Organ Function (Moderated Digital Poster Session)
Sunday, November 17, 2024, 10:40 a.m. (CST), 11:40 a.m. (EST)
Presenting Author: Lynne Krohn
Home Blood Pressure Reductions with Zilebesiran in Patients with Mild-To-Moderate Hypertension are Consistent with Ambulatory and Office Blood Pressure Reductions in the KARDIA-1 Study
Poster MDP746: Session: Hypertension Gets Exciting! New Drugs! New Technologies! What Should I Choose? (Moderated Digital Poster Session)
Sunday, November 17, 2024, 3:45 p.m. (CST), 4:45 p.m. (EST)